← Back to Search

Digital Community for HIV & Hepatitis C Prevention

N/A

Recruiting

Led By Dolores Albarracin, PhD

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Under the age of 18

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, session 2 [experimental condition only], immediate follow-up (3 weeks), 3 months, 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial studies how to reduce HIV & HCV infections in areas with high risk due to injection drug use.

Who is the study for?

This trial is for adults living in specific high-risk areas of Appalachia and the Midwest, where there's a concern about HIV and Hepatitis C due to injection drug use. It includes those who have used illicit substances within the last month as well as those who haven't in the past year.

What is being tested?

The study tests a 'Virtual Community Intervention' against the usual health practices (Standard of Care) to see if it can improve health outcomes related to infectious diseases like HIV and Hepatitis C in rural communities.

What are the potential side effects?

Since this intervention is non-medical and involves digital community support, direct physical side effects are not expected. However, participants may experience stress or discomfort from discussing personal health issues online.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am younger than 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, session 2 [experimental condition only], immediate follow-up (3 weeks), 3 months, 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, session 2 [experimental condition only], immediate follow-up (3 weeks), 3 months, 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, session 2 [experimental condition only], immediate follow-up (3 weeks), 3 months, 6 months for reporting.